News

Dr Kelsey will manage the operational and strategic activities of the company’s oncology programs. He will report to Thomas Okarma, Geron’s president and CEO. Mr Movahhed will be

This will be in combination with substantial investment on clinical research for generating India-specific data for both, new product development, and marketing existing products. The company plans to

In the first quarter of 2009, the company revenue increase was primarily due to $76.9 million of incremental revenue provided by our Health Management segment principally as a

The Phase III studies, known as Achieve 1 and Achieve 2/3, evaluated albinterferon alfa-2b versus peginterferon alfa-2a, in combination with ribavirin, for use in the treatment of interferon-naive

In this study, Omnaris HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction in the 24-hour reflective total nasal symptom score (TNSS), which assesses the

Marcus Hedenskog, head of the newly formed Vitrolife KK, said: “The establishment of a company of our own, with an office in Tokyo, will markedly increase our opportunities

The probe is an advanced molecular diagnostic test kit that uses DNA probes for early detection and monitoring the course of bladder cancer. It is designed to detect

GSK1838262 did not demonstrate a statistically significant improvement on the primary endpoint when compared to placebo, based on the change from baseline to end of treatment on the

The study combined two oral DAAs, R7227 and R7128, for the first time in patients. There were no serious adverse events reported during the 14 days of dosing,